S&P 500 7,370.81 â–ŧ 101.98 (-1.36%) DOW 51,692.85 â–ŧ 19.86 (-0.04%) NASDAQ 25,611.30 â–ŧ 555.30 (-2.12%) US Markets Closed â€ĸ 09:26 PM ET

NNNN

Anbio Biotechnology

Price Chart
Latest Quote

$15.70

-0.77 (-4.68%)
Current Price
Previous Close $16.47
Open $17.50
Day High $17.50
Day Low $15.50
Volume 28,132
Fetched: 2026-06-23T22:33:15
Stock Information
Shares Outstanding 43.89M
Cash Equivalents $11.90M
Revenue $8.65M
Net Income $6.40M
Sector Healthcare
Industry Medical Instruments & Supplies
Market Cap $689.09M
P/E Ratio 104.67
EPS (TTM) $0.15
Exchange NGM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$677.19M
Sales$8.65M
Income$6.40M
Book/sh$0.69
Cash/sh$0.27
Employees27
Financial Ratios
Quick Ratio177.13
Current Ratio344.31
Returns & Margins
ROA14.66%
ROE27.05%
Gross Margin87.24%
Operating Margin59.09%
Profit Margin74.06%
Ownership
Insider Ownership4.78%
Institutional Ownership4.90%
Insider & Institutional transactions data not available
Valuation Ratios
P/S79.69
P/B22.85
Analyst Data
Recommendationnone
Technical Indicators
SMA20$22.75
SMA50$25.86
SMA200$27.83
RSI10.87
ATR2.9592
Shares Float39.69M
Short Float0.20%
Short Ratio3.81
Rel Volume0.93
Performance History
Week-6.60%
Month-48.10%
Quarter-31.35%
6 Months-48.10%
YTD-46.74%
Year-2.48%
10 Years+172.10%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-23 $15.70 28,132
2026-06-22 $16.47 32,200
2026-06-18 $16.64 18,200
2026-06-17 $15.86 11,400
2026-06-16 $16.14 41,500
2026-06-15 $16.81 19,900
2026-06-12 $15.59 33,500
2026-06-11 $16.44 54,900
2026-06-10 $16.43 20,200
2026-06-09 $16.16 35,600
2026-06-08 $17.22 61,400
2026-06-05 $22.99 60,800
2026-06-04 $27.01 28,400
2026-06-03 $28.51 42,700
2026-06-02 $32.12 13,500
2026-06-01 $30.17 27,600
2026-05-29 $34.41 8,200
2026-05-28 $34.44 18,600
2026-05-27 $32.79 20,300
2026-05-26 $33.01 30,400
About Anbio Biotechnology

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

📰 Latest News
US Undiscovered Gems To Watch In May 2026
Simply Wall St. â€ĸ 2026-05-29T17:33:29Z
Article thumbnail
Discover 3 Undiscovered Gems in the US Market
Simply Wall St. â€ĸ 2026-05-29T11:33:23Z
Article thumbnail
Uncovering US Market's 3 Undiscovered Gems With Potential
Simply Wall St. â€ĸ 2026-05-28T17:33:22Z
Article thumbnail
Discovering US Undiscovered Gems In May 2026
Simply Wall St. â€ĸ 2026-05-21T17:33:23Z
Article thumbnail
Undiscovered Gems in the US Market May 2026
Simply Wall St. â€ĸ 2026-05-21T11:33:22Z
Article thumbnail
Uncovering 3 Undiscovered Gems in the US Market
Simply Wall St. â€ĸ 2026-05-18T11:33:41Z
Article thumbnail
Discovering Hidden Opportunities in US Stocks with Strong Potential
Simply Wall St. â€ĸ 2026-05-15T17:33:06Z
Article thumbnail
Discovering US Market's Undiscovered Gems in May 2026
Simply Wall St. â€ĸ 2026-05-07T17:33:50Z
Article thumbnail
Undiscovered Gems in the US Market for May 2026
Simply Wall St. â€ĸ 2026-05-07T11:33:12Z
Article thumbnail
Undiscovered Gems In The US Market Featuring 3 Promising Small Caps
Simply Wall St. â€ĸ 2026-05-06T17:33:23Z
Article thumbnail
Period:
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $1,103,682 $2,299,762 $3,351,121 $10,980,847
Cost Of Revenue $1,103,682 $2,299,762 $3,351,121 $10,980,847
Total Revenue $8,646,844 $8,185,146 $6,711,990 $23,544,652
Operating Revenue $8,646,844 $8,185,146 $6,711,990 $23,544,652
Expenses
Total Expenses $2,879,104 $6,189,779 $4,751,061 $13,349,064
Other Income Expense $493,700 $39,964 $127,444 $-218,657
Other Non Operating Income Expenses $138 $19,495 $8,025 $43,562
Net Non Operating Interest Income Expense $142,023 $337,511 $165,336 $34,246
Operating Expense $1,775,422 $3,890,017 $1,399,940 $2,368,217
Interest Expense - $0 $0 $7,999
Interest Expense Non Operating - $0 $0 $7,999
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $6,403,463 $2,372,842 $2,253,709 $10,011,177
Net Interest Income $142,023 $337,511 $165,336 $34,246
Interest Income $142,023 $337,511 $165,336 $42,245
Normalized Income $5,909,901 $2,352,373 $2,134,290 $10,273,396
Net Income From Continuing And Discontinued Operation $6,403,463 $2,372,842 $2,253,709 $10,011,177
Total Operating Income As Reported $5,767,740 $1,995,367 $1,960,929 $10,195,588
Net Income Common Stockholders $6,403,463 $2,372,842 $2,253,709 $10,011,177
Net Income $6,403,463 $2,372,842 $2,253,709 $10,011,177
Net Income Including Noncontrolling Interests $6,403,463 $2,372,842 $2,253,709 $10,011,177
Net Income Continuous Operations $6,403,463 $2,372,842 $2,253,709 $10,011,177
Pretax Income $6,403,463 $2,372,842 $2,253,709 $10,011,177
Interest Income Non Operating $142,023 $337,511 $165,336 $42,245
Operating Income $5,767,740 $1,995,367 $1,960,929 $10,195,588
Gross Profit $7,543,162 $5,885,384 $3,360,869 $12,563,805
Per Share
Diluted EPS - $0.05 $0.01 $0.07
Basic EPS - $0.05 $0.02 $0.07
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $5,274,178 $1,974,898 $1,853,569 $10,287,647
Total Unusual Items $493,562 $20,469 $119,419 $-262,219
Total Unusual Items Excluding Goodwill $493,562 $20,469 $119,419 $-262,219
EBITDA (Bullshit earnings) $5,767,740 $1,995,367 $1,972,988 $10,025,428
EBIT $5,767,740 $1,995,367 $1,960,929 $10,019,176
Diluted NI Availto Com Stockholders $6,403,463 $2,372,842 $2,253,709 $10,011,177
Tax Provision $0 $0 $0 $0
Gain On Sale Of Security $493,562 $20,469 $119,419 $-262,219
Research And Development $201,305 $454,227 $134,700 $200,000
Selling General And Administration $1,574,117 $3,435,790 $1,265,240 $2,168,217
Reconciled Depreciation - $0 $12,059 $6,252
Diluted Average Shares - $43,891,200 $187,782,400 $143,891,200
Basic Average Shares - $43,891,200 $143,891,200 $143,891,200
Fetched: 2026-06-23
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $30,155,023 $17,191,550 $14,818,708 $12,546,990
Total Assets $30,242,859 $18,921,784 $15,811,768 $13,958,275
Total Non Current Assets $0 $387,440 $62,137 $15,048
Non Current Deferred Assets $0 $387,440 $42,835 $0
Current Assets $30,242,859 $18,534,344 $15,749,631 $13,943,227
Prepaid Assets $14,684,716 $5,708,691 $4,176,695 $4,916,718
Receivables $3,656,912 $1,064,794 $1,884,960 $3,581
Other Receivables $948 - - -
Accounts Receivable $3,655,964 $1,064,794 $1,884,960 $0
Allowance For Doubtful Accounts Receivable $0 $0 $0 $0
Gross Accounts Receivable $3,655,964 $1,064,794 $1,884,960 $0
Cash Cash Equivalents And Short Term Investments $11,901,231 $11,760,859 $9,687,976 $8,669,056
Cash And Cash Equivalents $7,766,738 $11,760,859 $9,687,976 $7,102,271
Non Current Prepaid Assets - $0 $1,293 $2,989
Non Current Accounts Receivable - - $18,009 -
Inventory - - $0 $353,872
Taxes Receivable - - $0 $3,581
Liabilities
Total Liabilities Net Minority Interest $87,836 $1,730,234 $993,060 $1,411,285
Total Non Current Liabilities Net Minority Interest $0 $0 $0 $0
Current Liabilities $87,836 $1,730,234 $993,060 $1,411,285
Payables And Accrued Expenses $87,836 $1,730,234 $993,060 $1,411,285
Payables $87,836 $1,730,234 $993,060 $1,411,285
Other Payable $87,836 $104,979 $165,909 $3,243
Accounts Payable $0 $1,625,255 $827,151 $1,408,042
Other Current Liabilities - - $-1 -
Current Deferred Liabilities - - - $0
Equity
Common Stock Equity $30,155,023 $17,191,550 $14,818,708 $12,546,990
Total Equity Gross Minority Interest $30,155,023 $17,191,550 $14,818,708 $12,546,990
Stockholders Equity $30,155,023 $17,191,550 $14,818,708 $12,546,990
Retained Earnings $23,577,004 $17,173,541 $14,800,699 $12,546,990
Other
Ordinary Shares Number $43,891,200 $43,891,200 $43,891,200 $43,891,200
Share Issued $43,891,200 $43,891,200 $43,891,200 $43,891,200
Tangible Book Value $30,155,023 $17,191,550 $14,818,708 $12,546,990
Invested Capital $30,155,023 $17,191,550 $14,818,708 $12,546,990
Working Capital $30,155,023 $16,804,110 $14,756,571 $12,531,942
Total Capitalization $30,155,023 $17,191,550 $14,818,708 $12,546,990
Additional Paid In Capital $6,563,630 $3,780 $3,780 $0
Capital Stock $14,389 $14,229 $14,229 $0
Common Stock $14,389 $14,229 $14,229 $0
Other Short Term Investments $4,134,493 $0 $0 $1,566,785
Finished Goods - - $0 $353,872
Current Deferred Revenue - - - $0
Net PPE - - - $12,059
Gross PPE - - - $12,059
Other Properties - - - $12,059
Fetched: 2026-06-23
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-6,739,075 $2,080,387 $898,367 $4,448,846
Operating Activities
Operating Cash Flow $-6,739,075 $2,080,387 $898,367 $4,448,846
Cash Flow From Continuing Operating Activities $-6,739,075 $2,080,387 $898,367 $4,448,846
Operating Gains Losses $68,003 $-337,101 $-163,388 $-38,885
Investing Activities
Investing Cash Flow $-4,202,496 $337,101 $1,730,173 $-1,527,900
Cash Flow From Continuing Investing Activities $-4,202,496 $337,101 $1,730,173 $-1,527,900
Financing Activities
Issuance Of Capital Stock $7,230,000 $0 $0 -
Financing Cash Flow $6,947,450 $-344,605 $-42,835 $0
Cash Flow From Continuing Financing Activities $6,947,450 $-344,605 $-42,835 $0
Net Other Financing Charges $-282,550 $-344,605 $-42,835 -
Net Common Stock Issuance $7,230,000 $0 $0 -
Common Stock Issuance $7,230,000 $0 $0 -
Other
End Cash Position $7,766,738 $11,760,859 $9,687,976 $7,102,271
Beginning Cash Position $11,760,859 $9,687,976 $7,102,271 $4,181,325
Changes In Cash $-3,994,121 $2,072,883 $2,585,705 $2,920,946
Net Investment Purchase And Sale $-4,202,496 $337,101 $1,730,173 $-1,527,900
Sale Of Investment $15,217,504 $35,803,336 $20,274,423 $14,561,936
Purchase Of Investment $-19,420,000 $-35,466,235 $-18,544,250 $-16,089,836
Change In Working Capital $-13,210,541 $44,646 $-1,204,013 $-5,529,698
Change In Other Current Liabilities $-17,143 $-60,930 $162,666 $-505,068
Change In Payables And Accrued Expense $-1,625,255 $798,104 $-580,891 $-481,824
Change In Payable $-1,625,255 $798,104 $-580,891 $-481,824
Change In Account Payable $-1,625,255 $798,104 $-580,891 $-481,824
Change In Prepaid Assets $-8,976,973 $-1,512,694 $745,300 $-4,906,435
Change In Receivables $-2,591,170 $820,166 $-1,884,960 $717,500
Changes In Account Receivables $-2,591,170 $820,166 $-1,884,960 $717,500
Gain Loss On Investment Securities $68,003 $-337,101 $-163,388 $-38,885
Net Income From Continuing Operations $6,403,463 $2,372,842 $2,253,709 $10,011,177
Change In Inventory - $0 $353,872 $-353,871
Depreciation Amortization Depletion - $0 $12,059 $6,252
Depreciation And Amortization - $0 $12,059 $6,252
Depreciation - $0 $12,059 $6,252
Other Non Cash Items - - - $1
Fetched: 2026-06-23